| Recipient age–years |
53 (42, 67) |
| Male gender–no. (%) |
120 (59.7) |
| White race–no. (%) |
164 (82.0) |
| Diabetes–no. (%) |
77 (38.5) |
| Hypertension–no. (%) |
189 (94.5) |
| Cause of end stage renal disease–no. (%) |
|
| Diabetes: |
54 (27.0) |
| Glomerular disease: |
47 (23.5) |
| PCKD: |
17 (8.5) |
| Other: |
82 (41.0) |
| Re-transplants–no. (%) |
39 (19.5) |
| Dialysis at the time of evaluation–no. (%) |
119 (59.5) |
| Dialysis time (median months, interquartile range) |
26 (11, 44.5) |
| History of cardiovascular events (CVE)–no. (%) |
67 (33.5) |
| Left ventricular hypertrophy (LVH)–no. (%) |
68 (42.5) |
| Positive stress echocardiogram–no. (%) |
24 (15.6) |
| All-cause mortality–no. (%) |
15 (7.5) |
| Composite outcome (CVE and/or death) |
38 (19.0) |
| Transplant approval–no. (%) |
166 (83.4) |
| Transplanted–no. (%) |
84 (42.6) |
| Laboratory data |
median (interquartile range) |
| Hemoglobin (g/dL) |
11 (10.1, 11.9) |
| Serum albumin (g/dL) |
4.2 (3.9, 4.4) |
| Uric acid (g/dL) |
6.5 (5.2, 8.2) |
| Phosphorus (mg/dL) |
4.8 (4.1, 5.6) |
| Parathyroid hormone |
201.5 (107, 354) |
| Creatinine (mg/dL) |
5.7 (4, 8.8) |
| C-reactive protein (mg/L) |
2.7 (1.1, 7.4) |
| Cardiac troponin T (ng/mL) |
0.02 (0.005, 0.05) |
| Soluble ST2 (ng/mL) |
27.8 (19.3, 37.8) |
